U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Woman has new tongue made from leg muscle after mouth cancer operation
A WOMAN whose tongue is partly made with a portion of her leg following cancer is speaking out about it to help others recognise the symptoms of the disease. (Source: Daily Express - Health)
Source: Daily Express - Health - August 16, 2022 Category: Consumer Health News Source Type: news
Navidea posts revenue declines, net loss increases in Q2
Radiopharmaceutical developer Navidea Biopharmaceuticals reported a declin...Read more on AuntMinnie.comRelated Reading:
Navidea highlights research on melanoma, oral cancer
Navidea touts clinical study using PET/CT for HIV infection
Navidea touts early results of RA study
Navidea secures Indian regulatory approval for Lymphoseek
NYSE accepts Navidea bid to comply with stock listing rules (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 15, 2022 Category: Radiology Source Type: news
NHS dentist crisis sparks fears deadly mouth cancers are going undiagnosed
Routine dental appointments always involve checks for signs of the disease, which include inflamed or white patches in the mouth, and small lumps or blisters which are ignored by patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 13, 2022 Category: Consumer Health News Source Type: news
Menarini Group ’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer
Submission supported by results from the pivotal... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 11, 2022 Category: Drugs & Pharmacology Source Type: news
Taste Dysfunction in Head and Neck Cancer Due to Radiation Dose Taste Dysfunction in Head and Neck Cancer Due to Radiation Dose
Lowering the dose of radiotherapy delivered to the oral cavity could reduce the risk of taste dysfunction in patients with head and neck cancer, say researchers.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 5, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
European Commission Approves IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 4 August 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). The approval is based on the pivotal Phase 3 GLOW study that demonstrated superior progression-free survival (PFS) in patients treated with I+V versus chlorambucil-obinutuzumab (Clb+O), and the FD cohort of the Phase 2 CAPTIVATE study, which showed deep ...
Source: Johnson and Johnson - August 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Navidea highlights research on melanoma, oral cancer
Radiopharmaceutical developer Navidea Biopharmaceuticals is directing attentio...Read more on AuntMinnie.comRelated Reading:
Navidea touts clinical study using PET/CT for HIV infection
Navidea touts early results of RA study
Navidea secures Indian regulatory approval for Lymphoseek
NYSE accepts Navidea bid to comply with stock listing rules
Navidea reports revenue declines in Q4, all of 2021 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 2, 2022 Category: Radiology Source Type: news
'Rogue' Online Pharmacies Are Dispensing Cancer Drugs
(MedPage Today) -- Dozens of illegitimate online pharmacies are selling imatinib, an oral chemotherapy drug for chronic myeloid leukemia (CML), putting patients at risk for toxicities and treatment failures, researchers found.
Of 44 online pharmacies... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 29, 2022 Category: American Health Source Type: news
The Latest Breakthroughs That Could Help Bladder Cancer Patients
Toward the end of the 19th century, a New York City surgeon named Dr. William Coley purposely injected one of his patients with streptococcal bacteria. Coley wasn’t crazy. He hoped the bacterial infection would stimulate an immune response that would slow the spread of his patient’s cancer, which was inoperable. The experiment worked; the patient’s tumor shrank.
For the next 40 years, Coley and his research collaborators would test similar remedies on more than 1,000 cancer patients. They had failures but also many successes, especially among people with bone or soft-tissue cancers. Today, Coley is someti...
Source: TIME: Health - July 27, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT ® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations
July 26, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1b/2 CHRYSALIS-2 study (NCT04077463) cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw) with the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) lazertinib and platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations.[1] These findings and additional updates, including data on RYBREVANT® in combination with laze...
Source: Johnson and Johnson - July 26, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Why Not Everyone Should Take Paxlovid
It’s getting harder to avoid COVID-19, thanks to the dominance of BA.5 in the U.S. and the growing number of other Omicron subvariants. Fortunately, Pfizer’s antiviral treatment Paxlovid can minimize illness from the disease.
But it’s not meant for everyone. Only those who are at increased risk for severe disease from COVID-19 qualify for the drug, including people over age 12 who have weakened immune systems or other health conditions that increase risk of serious effects of COVID-19—like asthma, cancer, liver disease, lung disease, heart disease, and obesity. Paxlovid also comes with a list of pot...
Source: TIME: Health - July 22, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Cancer: Britons 'come forward' if you spot two tooth complaints says surgeon - hidden sign
CANCER can be defeated if caught early enough in its development. This is why catching the symptoms as soon as they arise is so important. With this in mind, Mr Alastair Fry, Consultant Oral and Maxillofacial Surgeon at Bupa's Cromwell Hospital, is urging Britons to "come forward" if you experience two tooth complaints. (Source: Daily Express - Health)
Source: Daily Express - Health - July 20, 2022 Category: Consumer Health News Source Type: news
Johnson & Johnson Reports Q2 2022 Results
New Brunswick, N.J. (July 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company’s market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare solutions to patients and consumers around the world.”OVERALL FINANCIAL RESULTS
expand
...
Source: Johnson and Johnson - July 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Local Doctors are Now the Frontline for COVID-19 Response. It ’ s Not Clear They ’ re All Ready.
The COVID-19 pandemic continues to evolve as the virus mutates to more contagious forms. Despite the new wave and continuing federal effort to address COVID-19, the pandemic response is shifting to local levels. We also need to recognize that health care providers are and will be playing an increasingly important role in COVID-19 control and treatment, similar to how they manage illnesses like influenza.
Tools to fight COVID-19 are freely available to health-care providers, including tests, vaccines, monoclonal antibodies, and antiviral medications. The CDC, White House, FDA, state and local departments of health, media, a...
Source: TIME: Health - July 14, 2022 Category: Consumer Health News Authors: Scott A. Rivkees Tags: Uncategorized COVID-19 freelance Source Type: news
